{"nctId":"NCT00195663","briefTitle":"Efficacy and Safety of Adalimumab and Methotrexate (MTX) Versus MTX Monotherapy in Subjects With Early Rheumatoid Arthritis","startDateStruct":{"date":"2000-12"},"conditions":["Early Rheumatoid Arthritis"],"count":799,"armGroups":[{"label":"Adalimumab","type":"EXPERIMENTAL","interventionNames":["Biological: Adalimumab","Drug: Methotrexate placebo"]},{"label":"Adalimumab + methotrexate","type":"EXPERIMENTAL","interventionNames":["Biological: Adalimumab","Drug: Methotrexate"]},{"label":"Methotrexate","type":"EXPERIMENTAL","interventionNames":["Drug: Methotrexate","Biological: Adalimumab placebo"]}],"interventions":[{"name":"Adalimumab","otherNames":["ABT-D2E7","Humira"]},{"name":"Methotrexate","otherNames":[]},{"name":"Adalimumab placebo","otherNames":[]},{"name":"Methotrexate placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subject was age 18 or older and in good health (Investigator discretion) with a recent stable medical history.\n* Diagnosis of rheumatoid arthritis (RA) as defined by the 1987-revised American College of Rheumatology (ACR) criteria, with a disease duration less than 3 years, at least 8 swollen joints out of the 66 joints assessed, at least 10 tender joints out of the 68 joints assessed, at least 1 joint erosion or rheumatoid factor (RF) positivity, erythrocyte sedimentation rate (ESR) \\>= 28 mm/1h or C-reactive protein (CRP) \\>= 1.5 mg/dl\n\nExclusion Criteria:\n\n* Chronic arthritis diagnosed before the age of 16\n* Preceding treatment with MTX, cyclophosphamide, cyclosporin, azathioprine or more than 2 other disease-modifying anti-rheumatic drugs (DMARDs)\n* Subject previously received anti-tumor necrosis factor (TNF) therapy\n* Permanently wheelchair-bound or bedridden patients\n* Subject considered by the investigator, for any reason, to be an unsuitable candidate for the study\n* Female subject who is pregnant or breast-feeding or considering becoming pregnant","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants Meeting American College of Rheumatology 50% (ACR50) Response Criteria at Week 52","description":"American College of Rheumatology 50% (ACR50) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met:\n\n* ≥ 50% improvement in tender joint count;\n* ≥ 50% improvement in swollen joint count; and\n* ≥ 50% improvement in at least 3 of the 5 following parameters:\n\n  * Patient's assessment of pain (measured on a 100 mm visual analog scale \\[VAS\\]);\n  * Patient's global assessment of disease activity (measured on a 100 mm VAS);\n  * Physician's global assessment of disease activity (measured on a 100 mm VAS);\n  * Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI));\n  * Acute phase reactant value (C-Reactive Protein).\n\nParticipants who withdrew early were considered non-responders.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"118","spread":null},{"groupId":"OG001","value":"113","spread":null},{"groupId":"OG002","value":"165","spread":null}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Modified Total Sharp Score (mTSS) at Week 52","description":"The modified Total Sharp Score (mTSS) is a measure of change in joint health. Digitized images of radiographs of hands and feet obtained at screening and Week 52 were scored in a blinded manner. Joints were scored for erosions on a scale from 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale from 0 (no damage) to 4 (ankylosis or complete dislocation). Erosion scores and narrowing scores were added to obtain the mTSS (range = 0 \\[normal\\] to 398 \\[maximal disease\\]). An increase in mTSS from Baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.7","spread":"12.7"},{"groupId":"OG001","value":"3.0","spread":"11.2"},{"groupId":"OG002","value":"1.3","spread":"6.5"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Health Assessment Questionnaire - Disability Index (HAQ-DI) at Week 52","description":"The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. Negative mean changes from Baseline in the overall score indicate improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"0.6"},{"groupId":"OG001","value":"-0.8","spread":"0.7"},{"groupId":"OG002","value":"-1.1","spread":"0.6"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Meeting American College of Rheumatology 50% (ACR50) Response Criteria at Week 104","description":"American College of Rheumatology 50% (ACR50) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met:\n\n* ≥ 50% improvement in tender joint count;\n* ≥ 50% improvement in swollen joint count; and\n* ≥ 50% improvement in at least 3 of the 5 following parameters:\n\n  * Patient's assessment of pain (measured on a 100 mm visual analog scale \\[VAS\\]);\n  * Patient's global assessment of disease activity (measured on a 100 mm VAS);\n  * Physician's global assessment of disease activity (measured on a 100 mm VAS);\n  * Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \\[HAQ-DI\\]);\n  * Acute phase reactant value (C-Reactive Protein).\n\nParticipants withdrawing early were considered non-responders.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"110","spread":null},{"groupId":"OG001","value":"101","spread":null},{"groupId":"OG002","value":"158","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Modified Total Sharp Score (mTSS) at Week 104","description":"The modified Total Sharp Score (mTSS) is a measure of change in joint health. Digitized images of radiographs of hands and feet obtained at screening and Week 104 were scored in a blinded manner. Joints were scored for erosions on a scale of 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale of 0 (no damage) to 4 (ankylosis or complete dislocation). Erosion scores and narrowing scores were added to obtain the mTSS (range = 0 \\[normal\\] to 398 \\[maximal disease\\]). An increase in mTSS from Baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.4","spread":"21.7"},{"groupId":"OG001","value":"5.5","spread":"15.8"},{"groupId":"OG002","value":"1.9","spread":"8.3"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Achieved Clinical Remission, Defined as a Disease Activity 28 (DAS28) Score < 2.6 at Week 52","description":"The DAS28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, C reactive protein, and general health were included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score \\>5.1 indicates high disease activity, a DAS28 score \\<3.2 indicates low disease activity, and a DAS28 score \\<2.6 indicates clinical remission.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53","spread":null},{"groupId":"OG001","value":"64","spread":null},{"groupId":"OG002","value":"115","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Physical Component of the Short Form-36 Health Status Survey (SF-36) at Week 52","description":"The SF-36 determined participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 comprise the physical component of the SF-36. Scores on each item were summed and averaged (range = 0-100); increases from Baseline indicate improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.5","spread":"9.6"},{"groupId":"OG001","value":"12.6","spread":"10.0"},{"groupId":"OG002","value":"16.7","spread":"10.2"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Major Clinical Response After 104 Weeks of Treatment","description":"Major clinical response was defined as an American College of Rheumatology 70% (ACR70) response for any six continuous months, over 104 weeks of treatment. A participant was a responder if the following criteria for improvement from Baseline were met:\n\n* ≥ 70% improvement in tender joint count;\n* ≥ 70% improvement in swollen joint count; and\n* ≥ 70% improvement in at least 3 of the 5 following parameters:\n\n  * Patient's assessment of pain (measured on a 100 mm visual analog scale \\[VAS\\]);\n  * Patient's global assessment of disease activity (measured on a 100 mm VAS);\n  * Physician's global assessment of disease activity (measured on a 100 mm VAS);\n  * Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \\[HAQ-DI\\]);\n  * Acute phase reactant value (C-Reactive Protein).\n\nParticipants withdrawing early were non-responders.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70","spread":null},{"groupId":"OG001","value":"67","spread":null},{"groupId":"OG002","value":"130","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Mental Component of the Short Form-36 Health Status Survey (SF-36) at Week 52","description":"The SF-36 determined participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 5-8 comprise the mental component of the SF-36. Scores on each item were summed and averaged (range = 0-100); increases from Baseline indicate improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.5","spread":"11.0"},{"groupId":"OG001","value":"7.1","spread":"12.3"},{"groupId":"OG002","value":"7.2","spread":"13.1"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Meeting American College of Rheumatology 50% (ACR50) Response Criteria at Weeks 26 and 76","description":"American College of Rheumatology 50% (ACR50) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met:\n\n* ≥ 50% improvement in tender joint count;\n* ≥ 50% improvement in swollen joint count; and\n* ≥ 50% improvement in at least 3 of the 5 following parameters:\n\n  * Patient's assessment of pain (measured on a 100 mm visual analog scale \\[VAS\\]);\n  * Patient's global assessment of disease activity (measured on a 100 mm VAS);\n  * Physician's global assessment of disease activity (measured on a 100 mm VAS);\n  * Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \\[HAQ-DI\\]);\n  * Acute phase reactant value (C-Reactive Protein).\n\nParticipants withdrawing early were considered non-responders.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"104","spread":null},{"groupId":"OG001","value":"96","spread":null},{"groupId":"OG002","value":"157","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"114","spread":null},{"groupId":"OG001","value":"114","spread":null},{"groupId":"OG002","value":"161","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Meeting American College of Rheumatology 20% (ACR20) Response Criteria During the Double-blind Phase","description":"American College of Rheumatology 20% (ACR20) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met:\n\n* ≥ 20% improvement in tender joint count;\n* ≥ 20% improvement in swollen joint count; and\n* ≥ 20% improvement in at least 3 of the 5 following parameters:\n\n  * Patient's assessment of pain (measured on a 100 mm visual analog scale \\[VAS\\]);\n  * Patient's global assessment of disease activity (measured on a 100 mm VAS);\n  * Physician's global assessment of disease activity (measured on a 100 mm VAS);\n  * Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \\[HAQ-DI\\]);\n  * Acute phase reactant value (C-Reactive Protein).\n\nParticipants withdrawing early were considered non-responders.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"158","spread":null},{"groupId":"OG001","value":"146","spread":null},{"groupId":"OG002","value":"184","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"161","spread":null},{"groupId":"OG001","value":"149","spread":null},{"groupId":"OG002","value":"195","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"154","spread":null},{"groupId":"OG001","value":"137","spread":null},{"groupId":"OG002","value":"185","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"144","spread":null},{"groupId":"OG001","value":"135","spread":null},{"groupId":"OG002","value":"186","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Meeting American College of Rheumatology 70% (ACR70) Response Criteria During the Double-blind Phase","description":"American College of Rheumatology 70% (ACR70) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met:\n\n* ≥ 70% improvement in tender joint count;\n* ≥ 70% improvement in swollen joint count; and\n* ≥ 70% improvement in at least 3 of the 5 following parameters:\n\n  * Patient's assessment of pain (measured on a 100 mm visual analog scale \\[VAS\\]);\n  * Patient's global assessment of disease activity (measured on a 100 mm VAS);\n  * Physician's global assessment of disease activity (measured on a 100 mm VAS);\n  * Patient's self-assessment of physical function (Health Assessment Questionnaire Disability Index \\[HAQ-DI\\]);\n  * Acute phase reactant value (C-Reactive Protein).\n\nParticipants withdrawing early were considered non-responders.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57","spread":null},{"groupId":"OG001","value":"54","spread":null},{"groupId":"OG002","value":"114","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70","spread":null},{"groupId":"OG001","value":"71","spread":null},{"groupId":"OG002","value":"122","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75","spread":null},{"groupId":"OG001","value":"79","spread":null},{"groupId":"OG002","value":"127","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73","spread":null},{"groupId":"OG001","value":"77","spread":null},{"groupId":"OG002","value":"125","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Health Assessment Questionnaire - Disability Index (HAQ-DI) During the Double-blind Treatment Phase","description":"The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. Negative mean changes from Baseline in the overall score indicate improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"0.6"},{"groupId":"OG001","value":"-0.6","spread":"0.6"},{"groupId":"OG002","value":"-0.8","spread":"0.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"0.6"},{"groupId":"OG001","value":"-0.8","spread":"0.7"},{"groupId":"OG002","value":"-0.9","spread":"0.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"0.6"},{"groupId":"OG001","value":"-0.9","spread":"0.7"},{"groupId":"OG002","value":"-1.0","spread":"0.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.9","spread":"0.6"},{"groupId":"OG001","value":"-0.9","spread":"0.6"},{"groupId":"OG002","value":"-1.0","spread":"0.7"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Improvement in the HAQ-DI Score ≥ 0.3 During the Double-blind Treatment Phase","description":"The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"172","spread":null},{"groupId":"OG001","value":"169","spread":null},{"groupId":"OG002","value":"200","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"158","spread":null},{"groupId":"OG001","value":"151","spread":null},{"groupId":"OG002","value":"186","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"144","spread":null},{"groupId":"OG001","value":"145","spread":null},{"groupId":"OG002","value":"173","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"137","spread":null},{"groupId":"OG001","value":"132","spread":null},{"groupId":"OG002","value":"171","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Health Utilities Index Mark 2 and Mark 3 (HUI 2/3) During the Double-blind Treatment Phase","description":"The HUI 2/3 is an assessment of various aspects of participants' health and ability to perform various tasks on a day-to-day basis, including reading, seeing, hearing, speaking, general outlook on life, pain/discomfort, ability to walk, use of hands, memory, ability to think/solve, and ability to perform basic activities such as eating, bathing, and dressing. The HUI 2/3 is a combined 15-item questionnaire based on a recall period of the previous 4 weeks. HUI-2 and HUI-3 scores are calculated independently. The HUI-2 score includes 6 attributes: Sensation, Mobility, Emotion, Cognition, Self-Care, and Pain. The HUI-3 score is comprised of 8 attributes: Vision, Hearing, Speech, Ambulation, Dexterity, Emotion, Cognition, and Pain.\n\nThe range of each score is from 0 (dead) to 1 (perfect health). An increase from Baseline indicates improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"0.2"},{"groupId":"OG001","value":"0.2","spread":"0.2"},{"groupId":"OG002","value":"0.2","spread":"0.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"0.2"},{"groupId":"OG001","value":"0.2","spread":"0.2"},{"groupId":"OG002","value":"0.2","spread":"0.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"0.2"},{"groupId":"OG001","value":"0.2","spread":"0.2"},{"groupId":"OG002","value":"0.2","spread":"0.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"0.3"},{"groupId":"OG001","value":"0.3","spread":"0.3"},{"groupId":"OG002","value":"0.3","spread":"0.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"0.3"},{"groupId":"OG001","value":"0.3","spread":"0.3"},{"groupId":"OG002","value":"0.4","spread":"0.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"0.2"},{"groupId":"OG001","value":"0.4","spread":"0.3"},{"groupId":"OG002","value":"0.4","spread":"0.3"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Short Form-36 Health Status Survey (SF-36) During the Double-blind Treatment Phase","description":"The SF-36 determined participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 comprise the physical component and items 5-8 comprise the mental component of the SF-36. Scores on each item were summed and averaged (range = 0-100); increases from Baseline indicate improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.2","spread":"10.0"},{"groupId":"OG001","value":"10.8","spread":"10.2"},{"groupId":"OG002","value":"14.7","spread":"10.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.4","spread":"10.3"},{"groupId":"OG001","value":"13.4","spread":"9.7"},{"groupId":"OG002","value":"16.8","spread":"11.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.0","spread":"11.6"},{"groupId":"OG001","value":"5.2","spread":"13.5"},{"groupId":"OG002","value":"6.3","spread":"12.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.1","spread":"10.9"},{"groupId":"OG001","value":"6.6","spread":"13.5"},{"groupId":"OG002","value":"6.8","spread":"12.0"}]}]}]},{"type":"SECONDARY","title":"Numeric American College of Rheumatology (ACR-N) During the Double-blind Treatment Phase","description":"ACR-N is a composite, continuous variable which measures the percentage of improvement from Baseline in individual participants based on the 7 core set variables of the ACR. ACR-N is defined as the smallest percent change from Baseline of 3 measures: tender joint counts (TJC), swollen joint counts (SJC), and the median percent improvement in the 5 remaining measures (Patient's Assessment of Pain, Physician's Global Assessment of Disease Activity, Patient's Global Assessment of Disease Activity, Health Assessment Questionnaire - Disability Index \\[HAQ-DI\\], and C-Reactive Protein). A positive ACR-N value indicates improvement; a negative ACR-N value indicates worsening; ACR-N of 0 indicates no change.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44.7","spread":"42.2"},{"groupId":"OG001","value":"39.1","spread":"43.3"},{"groupId":"OG002","value":"57.0","spread":"42.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.2","spread":"48.2"},{"groupId":"OG001","value":"44.4","spread":"52.2"},{"groupId":"OG002","value":"66.3","spread":"34.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.1","spread":"38.1"},{"groupId":"OG001","value":"51.5","spread":"56.8"},{"groupId":"OG002","value":"68.8","spread":"31.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57.3","spread":"37.1"},{"groupId":"OG001","value":"54.0","spread":"42.7"},{"groupId":"OG002","value":"71.4","spread":"31.0"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Disease Activity Score (DAS28) During the Double-blind Treatment Phase","description":"The DAS28 is a composite score of rheumatoid arthritis disease activity derived from the following variables:\n\n* 28 tender joint counts,\n* 28 swollen joint counts,\n* C-reactive protein, and\n* Patient's global assessment of disease activity.\n\nScores on the DAS28 range from 0 to 10. A DAS28 score higher than 5.1 indicates high disease activity, a DAS28 score less than 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.6","spread":"1.3"},{"groupId":"OG001","value":"-2.4","spread":"1.4"},{"groupId":"OG002","value":"-3.2","spread":"1.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.8","spread":"1.4"},{"groupId":"OG001","value":"-2.8","spread":"1.5"},{"groupId":"OG002","value":"-3.6","spread":"1.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.1","spread":"1.2"},{"groupId":"OG001","value":"-3.0","spread":"1.5"},{"groupId":"OG002","value":"-3.7","spread":"1.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.1","spread":"1.4"},{"groupId":"OG001","value":"-3.2","spread":"1.4"},{"groupId":"OG002","value":"-3.8","spread":"1.3"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Joint Erosion Score During the Double-blind Treatment Period","description":"Digitized images of radiographs of hands and feet obtained at screening and during the study were scored in a blinded manner. Joints on each hand/wrist (17 joints) and each forefoot (6 joints) were scored for erosions on a scale of 0 = no erosions; 1 = 1 discrete erosion or ≤20% joint involvement; 2 = 2 separate quadrants with erosion or 21-40% joint involvement; 3 = 3 separate quadrants with erosion or 41-60% joint involvement; 4 = all 4 quadrants with erosion or 61-80% joint involvement; and 5 = extensive destruction with \\>80% joint involvement. Scores were summed to calculate the total erosion score, which ranges from 0 (no erosion)to 230 (worst). A large increase in erosion score is indicative of worsening, whereas a small change or no change is indicative of inhibition of joint erosion.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.7","spread":"8.4"},{"groupId":"OG001","value":"1.7","spread":"5.7"},{"groupId":"OG002","value":"0.8","spread":"3.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.4","spread":"14.3"},{"groupId":"OG001","value":"3.0","spread":"8.3"},{"groupId":"OG002","value":"1.0","spread":"4.7"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Joint Space Narrowing Score During the Double-blind Treatment Period","description":"Digitized images of radiographs of hands and feet obtained at screening and during the study were scored in a blinded manner. Joint space narrowing (JSN) scores were recorded for each hand/wrist (16 joints) and each forefoot (5 joints) on a 5-point scale (0 = no narrowing; 1 = up to 25% narrowing; 2 = 26-65% narrowing; 3 = 66-99% narrowing; and 4 = complete narrowing). Scores were summed to calculate the total score ranging from 0 (no narrowing) to 168 (maximum narrowing). A large increase in joint narrowing score is indicative of worsening, whereas a small change or no change is indicative of inhibition of JSN.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":"6.3"},{"groupId":"OG001","value":"1.3","spread":"6.6"},{"groupId":"OG002","value":"0.5","spread":"4.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","spread":"10.9"},{"groupId":"OG001","value":"2.6","spread":"9.5"},{"groupId":"OG002","value":"0.9","spread":"5.1"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With No Worsening in Modified Total Sharp Score or Components During the Double-blind Treatment Phase","description":"The number of participants with no worsening in the modified Total Sharp Score (mTSS) and in erosion and joint space narrowing (JSN) scores, where no worsening is defined as a change from Baseline of ≤ 0 in mTSS, erosion score and JSN score, at Weeks 52 and 104.\n\nDigitized images of radiographs of hands and feet obtained at screening and during the study were scored in a blinded manner. Joints were scored for erosions on a scale of 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale of 0 (no damage) to 4 (ankylosis or complete dislocation). Erosion scores and narrowing scores were added to obtain the mTSS (range = 0 \\[normal\\] to 398 \\[maximal disease\\]). An increase in mTSS from Baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78","spread":null},{"groupId":"OG001","value":"112","spread":null},{"groupId":"OG002","value":"141","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70","spread":null},{"groupId":"OG001","value":"105","spread":null},{"groupId":"OG002","value":"136","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91","spread":null},{"groupId":"OG001","value":"133","spread":null},{"groupId":"OG002","value":"158","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81","spread":null},{"groupId":"OG001","value":"121","spread":null},{"groupId":"OG002","value":"148","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"127","spread":null},{"groupId":"OG001","value":"159","spread":null},{"groupId":"OG002","value":"190","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"112","spread":null},{"groupId":"OG001","value":"147","spread":null},{"groupId":"OG002","value":"175","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With No Erosions at Baseline and No New Erosions at Weeks 52 and 104","description":"The number of participants with no erosions at Baseline and no erosions at Weeks 52 and 104, where no erosions and no new erosions are defined as an erosion score = 0.\n\nDigitized images of radiographs of hands and feet obtained at screening and during the study were scored in a blinded manner. Joints on each hand/wrist (17 joints) and each forefoot (6 joints) were scored for erosions on a scale of 0 = no erosions; 1 = 1 discrete erosion or ≤20% joint involvement; 2 = 2 separate quadrants with erosion or 21-40% joint involvement; 3 = 3 separate quadrants with erosion or 41-60% joint involvement; 4 = all 4 quadrants with erosion or 61-80% joint involvement; and 5 = extensive destruction with \\>80% joint involvement. Scores were summed to calculate the total erosion score, which ranges from 0 (no erosion) to 230 (worst).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"10","spread":null},{"groupId":"OG002","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"11","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Non-Involved Joints at Baseline and No Newly Involved Joints at Weeks 52 and 104","description":"Number of participants with non-involved joints at Baseline and no newly involved joints at Weeks 52 and 104, where involved joints or no newly involved joints are defined as modified Total Sharp Score (mTSS) = 0.\n\nDigitized images of radiographs of hands and feet obtained at screening and during the study were scored in a blinded manner. Joints were scored for erosions on a scale of 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale of 0 (no damage) to 4 (ankylosis or complete dislocation). Erosion scores and narrowing scores were added to obtain the mTSS (range = 0 \\[normal\\] to 398 \\[maximal disease\\]).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Meeting ACR20 Response Criteria Over 10 Years by Adalimumab Exposure","description":"American College of Rheumatology 20% (ACR20) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met:\n\n* ≥ 20% improvement in tender joint count;\n* ≥ 20% improvement in swollen joint count; and\n* ≥ 20% improvement in at least 3 of the 5 following parameters:\n\n  * Patient's assessment of pain (measured on a 100 mm visual analog scale \\[VAS\\]);\n  * Patient's global assessment of disease activity (measured on a 100 mm VAS);\n  * Physician's global assessment of disease activity (measured on a 100 mm VAS);\n  * Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \\[HAQ-DI\\]);\n  * Acute phase reactant value (C-Reactive Protein).\n\nBaseline is the last value prior to the first dose of adalimumab. For participants randomized to the methotrexate (MTX) arm in the double-blind (DB) phase, Baseline was the last visit prior to the first adalimumab dose at Week 106 of the open-label (OL) phase.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"340","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"332","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"231","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"154","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Meeting ACR50 Response Criteria Over 10 Years by Adalimumab Exposure","description":"American College of Rheumatology 50% (ACR50) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met:\n\n* ≥ 50% improvement in tender joint count;\n* ≥ 50% improvement in swollen joint count; and\n* ≥ 50% improvement in at least 3 of the 5 following parameters:\n\n  * Patient's assessment of pain (measured on a 100 mm visual analog scale \\[VAS\\]);\n  * Patient's global assessment of disease activity (measured on a 100 mm VAS);\n  * Physician's global assessment of disease activity (measured on a 100 mm VAS);\n  * Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \\[HAQ-DI\\]);\n  * Acute phase reactant value (C-Reactive Protein).\n\nBaseline is the last value prior to the first dose of adalimumab. For patients randomized to the methotrexate (MTX) arm in the double-blind (DB) phase, Baseline was the last visit prior to the first adalimumab dose at Week 106 of the open-label (OL) phase.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"269","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"266","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"194","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"127","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Meeting ACR70 Response Criteria Over 10 Years by Adalimumab Exposure","description":"American College of Rheumatology 70% (ACR70) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met:\n\n* ≥ 70% improvement in tender joint count;\n* ≥ 70% improvement in swollen joint count; and\n* ≥ 70% improvement in at least 3 of the 5 following parameters:\n\n  * Patient's assessment of pain (measured on a 100 mm visual analog scale \\[VAS\\]);\n  * Patient's global assessment of disease activity (measured on a 100 mm VAS);\n  * Physician's global assessment of disease activity (measured on a 100 mm VAS);\n  * Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \\[HAQ-DI\\]);\n  * Acute phase reactant value (C-Reactive Protein).\n\nBaseline is the last value prior to the first dose of adalimumab. For patients randomized to the methotrexate (MTX) arm in the double-blind (DB) phase, Baseline was the last visit prior to the first adalimumab dose at Week 106 of the open-label (OL) phase.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"186","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"207","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"153","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"102","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Health Assessment Questionnaire - Disability Index (HAQ-DI) Over 10 Years by Adalimumab Exposure","description":"The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. Negative mean changes from Baseline in the overall score indicate improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.9","spread":"0.68"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.9","spread":"0.70"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":"0.73"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.9","spread":"0.73"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in DAS28 Over 10 Years by Adalimumab Exposure","description":"The DAS28 is a composite score of rheumatoid arthritis disease activity derived from the following variables:\n\n* 28 tender joint counts,\n* 28 swollen joint counts,\n* C-reactive protein, and\n* Patient's global assessment of disease activity.\n\nScores on the DAS28 range from 0 to 10. A DAS28 score higher than 5.1 indicates high disease activity, a DAS28 score less than 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.2","spread":"1.49"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.3","spread":"1.61"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.8","spread":"1.93"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.9","spread":"1.29"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With DAS28 < 2.6 and < 3.2 Over 10 Years by Adalimumab Exposure","description":"The DAS28 is a composite score of rheumatoid arthritis disease activity derived from the following variables:\n\n* 28 tender joint counts,\n* 28 swollen joint counts,\n* C-reactive protein, and\n* Patient's global assessment of disease activity.\n\nScores on the DAS28 range from 0 to 10. A DAS28 score higher than 5.1 indicates high disease activity, a DAS28 score less than 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"173","spread":null},{"groupId":"OG001","value":"244","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"215","spread":null},{"groupId":"OG001","value":"271","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"190","spread":null},{"groupId":"OG001","value":"244","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"109","spread":null},{"groupId":"OG001","value":"135","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Modified Total Sharp Score (mTSS) Over 10 Years","description":"The modified TSS (mTSS) is a measure of change in joint health. Digitized images of radiographs of hands and feet obtained at screening and during the study were scored in a blinded manner. Joints were scored for erosions on a scale of 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale of 0 (no damage) to 4 (ankylosis or complete dislocation). Erosion scores and narrowing scores were added to obtain the mTSS (range = 0 \\[normal\\] to 398 \\[maximal disease\\]). An increase in mTSS from Baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.3","spread":"12.44"},{"groupId":"OG001","value":"5.1","spread":"9.63"},{"groupId":"OG002","value":"0.3","spread":"3.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.8","spread":"20.01"},{"groupId":"OG001","value":"9.2","spread":"15.21"},{"groupId":"OG002","value":"3.9","spread":"9.64"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With No Radiographic Progression Over 10 Years","description":"The modified Total Sharp Score (mTSS) is a measure of change in joint health. Digitized images of radiographs of hands and feet obtained at screening and during the study were scored in a blinded manner. Joints were scored for erosions on a scale of 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale of 0 (no damage) to 4 (ankylosis or complete dislocation). Erosion scores and narrowing scores were added to obtain the mTSS (range = 0 \\[normal\\] to 398 \\[maximal disease\\]). An increase in mTSS from Baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement. The number of participants with change from Baseline ≤ 0.5 and ≤ 0 is reported as a measure of no disease progression.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"40","spread":null},{"groupId":"OG002","value":"65","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"22","spread":null},{"groupId":"OG002","value":"33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"30","spread":null},{"groupId":"OG002","value":"51","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"16","spread":null},{"groupId":"OG002","value":"29","spread":null}]}]}]},{"type":"SECONDARY","title":"Composite Score of ACR50 Plus No Change in Modified Total Sharp Score","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Number of Participants With a Major Clinical Response Over 10 Years by Adalimumab Exposure","description":"A major clinical response was defined as maintenance of an ACR70 response for at least a 6-month continuous period at any time during the study following the first dose of adalimumab. A participant was a responder if the following criteria for improvement from Baseline were met:\n\n* ≥ 70% improvement in tender joint count;\n* ≥ 70% improvement in swollen joint count; and\n* ≥ 70% improvement in at least 3 of the 5 following parameters:\n\n  * Patient's assessment of pain (measured on a 100 mm visual analog scale \\[VAS\\]);\n  * Patient's global assessment of disease activity (measured on a 100 mm VAS);\n  * Physician's global assessment of disease activity (measured on a 100 mm VAS);\n  * Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \\[HAQ-DI\\]);\n  * Acute phase reactant value (C-Reactive Protein).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"273","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Improvement in HAQ-DI by 0.22 and 0.5 Units Over 10 Years by Adalimumab Exposure","description":"The Health Assessment Questionnaire - Disability Index (HAQ-DI) is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. A decrease in the HAQ-DI score represents an improvement in physical function; a clinically significant improvement is defined as a decrease of least 0.22 from Baseline in the HAQ-DI score. The number of participants with improvement in HAQ-DI of at least 0.22 and 0.5 units from Baseline is reported.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"353","spread":null},{"groupId":"OG001","value":"285","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"324","spread":null},{"groupId":"OG001","value":"265","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"239","spread":null},{"groupId":"OG001","value":"188","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"140","spread":null},{"groupId":"OG001","value":"112","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":47,"n":257},"commonTop":["Nasopharyngitis","Headache","Upper respiratory tract infection","Rheumatoid arthritis","Nausea"]}}}